Brief General Approach for the Investigations of the Most Common Primary Immunodeficiencies

Abstract

Primary immunodeficiencies are congenital disorders caused by defects in different elements of the immune system. Laboratory evaluation of primary immunodeficiencies (PIDs) is a complex process requiring a multi-tiered approach to accurately diagnose these heterogeneous disorders. Initial assessment typically involves a thorough clinical history and physical examination, focusing on recurrent infections, autoimmunity, and other associated symptoms. This is followed by a comprehensive laboratory workup designed to evaluate different components of the immune system. The first line of investigation often includes basic immunological tests, such as complete blood counts (CBC) with differential, assessing lymphocyte subsets (CD4+, CD8+, B cells, NK cells), and immunoglobulin levels (IgG, IgA, IgM). Significant deviations from established reference ranges may indicate specific immune deficiencies. For example, low IgG levels suggest hypogammaglobulinemia, while decreased lymphocyte counts point towards lymphopenia. Further evaluation might include assessment of antibody function through specific antibody titers against common pathogens (e.g., pneumococcus, tetanus, diphtheria). Functional assays constitute a crucial second tier of investigation, providing a deeper understanding of immune cell activity. These can encompass flow cytometry analysis to assess lymphocyte activation, proliferation, and surface marker expression; assessment of phagocytic function (e.g., neutrophil oxidative burst test); and in vitro assays to evaluate complement function. These tests help identify defects in cellular immunity, humoral immunity, or complement pathways. Genetic testing is increasingly important, offering molecular confirmation of suspected diagnoses. Next-generation sequencing (NGS) panels targeting a wide range of PID-associated genes are becoming the standard of care, allowing for rapid and comprehensive genetic analysis. Interpreting the results requires expertise and integration of clinical information with laboratory findings. A normal result for a single test does not exclude PID, as the defects can be subtle or affect specific immune components. Therefore, the diagnostic process is often iterative, with additional testing guided by initial results and evolving clinical presentations. Advancements in technology, including high-throughput screening and sophisticated molecular techniques, are constantly improving the accuracy and efficiency of PID diagnosis, ultimately leading to earlier intervention and improved patient outcomes. However, a strong clinical suspicion remains essential for initiating appropriate investigations.